Business Context and Reporting Period
Company: Radiopharm Theranostics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2025 (Specifically February 25, 2025)
Context: This filing serves to disclose two announcements made to the Australian Securities Exchange (ASX) regarding corporate governance and securities status.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of specific corporate events rather than a financial results statement.
Material Changes
- Director's Interest: A "Change of Director's Interest Notice" was issued, indicating a modification in the shareholding or financial interests of a company director.
- Securities Cessation: A "Notification of cessation of securities" was issued, indicating that certain securities (ticker: RAD) have ceased to be held or are no longer active in a specific context.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the disclosed changes in director interests and securities status.
Investor Verification Checklist
- Verify the specific details of the director whose interest changed and the nature of the change (e.g., acquisition, disposal, or option exercise).
- Confirm the specific class of securities referenced in the "cessation of securities" notice and the reason for the cessation.
- Review the attached exhibits (99.1 and 99.2) for the full text of the ASX announcements.